Endo Pharmaceuticals (ENDO) gains 6.2% after stating the FDA has approved a crush-resistant...

|About: Endo International plc (ENDP)|By:, SA News Editor

Endo Pharmaceuticals (ENDO) gains 6.2% after stating the FDA has approved a crush-resistant version of its Opana pain-relief drug, which will be patent-protected until Nov. 2023. Concerns have existed about the potential for the non-crush-resistant version of Opana to be abused.